Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin

BACKGROUND: Platinum compounds such as cisplatin and carboplatin are DNA crosslinking agents widely used for cancer chemotherapy. However, the effectiveness of platinum compounds is often tempered by the acquisition of cellular drug resistance. Until now, no pharmacological approach has successfully...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacquemont, Céline, Simon, Julian A, D'Andrea, Alan D, Taniguchi, Toshiyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478989/
https://www.ncbi.nlm.nih.gov/pubmed/22537224
http://dx.doi.org/10.1186/1476-4598-11-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478989/
https://www.ncbi.nlm.nih.gov/pubmed/22537224
http://dx.doi.org/10.1186/1476-4598-11-26

Ejemplares similares